VivoSeq
Ophthalmology

Uveitis

79

Pipeline Programs↗

17

Active Trials↗

32

Companies Involved↗

Uveitis is a moderately active landscape with 79 programs across 32 companies. The most active players are Eye Pharma, Horizon Therapeutics Ireland DAC, Amgen. 12 therapies are approved with 16 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

69/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eye Pharma

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1P

Prism Pharmaceuticals

1 program

Phase 1Sanofi logo

Sanofi

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

74 of 92 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody1617%Protein / enzyme11%Cell therapy11%

Small molecule leads; the ring shows all 92 classified programs, each share of the total. Modality classified for 99% of 95 pipeline programs.

Analysis

Trial Status

126

clinical trials

Completed64 · 51%
Terminated23 · 18%
Unknown status16 · 13%
Recruiting6 · 5%
Withdrawn6 · 5%
Active, not recruiting6 · 5%
Other5 · 4%

Clinical Trials

Trial Activity

126 trials

Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Recruiting·AAlimera Sciences·Phase 4·NCT06539481·25 enrolled
A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis
Recruiting·TTianjin Medical University·N/A·NCT05592717·15 enrolled
Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis
Recruiting·—·Phase 2·NCT02706704·32 enrolled
Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
Recruiting·UUniversity of Baghdad·Phase 1·NCT07145008·20 enrolled
Minocycline for Chronic Autoimmune Uveitis
Recruiting·SSun Yat-sen University·Phase 1/2·NCT05474729·10 enrolled
A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants
Recruiting·Regeneron logoRegeneron·Phase 1/2·NCT07218770·72 enrolled
Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis
Active, not recruiting·AAlimera Sciences·Phase 4·NCT05322070·125 enrolled
Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
Active, not recruiting·ZZhongshan Ophthalmic Center, Sun Yat-sen University·N/A·NCT06310837·128 enrolled
Incidence of Macular Edema in a Uveitis Population
Active, not recruiting·—·N/A·NCT06686641·1,550 enrolled
A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT04088409·30 enrolled
Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema
Active, not recruiting·—·Phase 2·NCT05608837·28 enrolled
Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV)
Active, not recruiting·BBio-Thera Solutions·Phase 4·NCT05180526·60 enrolled
Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis
Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT05105347·130 enrolled
Treatment FOr Corticosteroid Dependent UveitiS
Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06258915·120 enrolled
A Proof-of-concept Trial to EvaluAte the efficaCy and Safety Of Cell Therapy TRX103 in Patients With Active, Non-infectious Uveitis
Not yet recruiting·—·Phase 1·NCT07427628·18 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)